Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.25M | 774.10K | 553.20K | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.15M | 2.57M | 2.26M | -- | -- |
| Operating Income | -3.15M | -2.57M | -2.26M | -- | -- |
| Income Before Tax | -5.20M | -4.25M | -3.58M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.20 | -4.25 | -3.58 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.20M | -4.25M | -3.58M | -- | -- |
| EBIT | -3.15M | -2.57M | -2.26M | -- | -- |
| EBITDA | -3.12M | -2.51M | -2.18M | -- | -- |
| EPS Basic | -37.36 | -30.55 | -25.71 | -- | -- |
| Normalized Basic EPS | -18.46 | -15.35 | -13.51 | -- | -- |
| EPS Diluted | -37.36 | -30.55 | -25.71 | -- | -- |
| Normalized Diluted EPS | -18.46 | -15.35 | -13.51 | -- | -- |
| Average Basic Shares Outstanding | 557.20K | 557.10K | 556.90K | -- | -- |
| Average Diluted Shares Outstanding | 557.20K | 557.10K | 556.90K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |